Toshiba Appoints Rance M. Poehler as President & Chief Executive Officer for Retail Solutions Business
16.11.2020 19:00:00 EET | Business Wire | Press release
Toshiba Global Commerce Solutions today announced Rance M. Poehler is joining the company as its new President and Chief Executive Officer effective November 16, 2020. Poehler has more than 25 years of experience building and expanding business-to-business organizations in unique vertical markets including retail where he has led the development of end-to-end solutions for general retail, quick-service restaurant, hospitality, and other segments. In his role, he will be responsible for leading the company’s continued transformation as a trusted retail commerce solutions leader for its large and growing customer and partner community.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201116005083/en/
Rance M. Poehle, President & CEO, Toshiba Global Commerce Solutions (Photo: Business Wire)
Poehler replaces Scott Maccabe who had been appointed President & CEO since 2015. Maccabe is retiring from his role as President & CEO at Toshiba Global Commerce Solutions, while he remains in this capacity at Toshiba America Business Solutions. Poehler takes over effective immediately and will work closely with Maccabe to ensure a full and seamless transition of duties. We thank Scott Maccabe for his commitment, strong leadership and many contributions to the success and growth of the business.
“Rance Poehler is a highly accomplished business executive with a proven track-record for scaling businesses that are in a unique position to transform the industries they serve,” said Maccabe. “Rance brings the fortitude and execution prowess needed to transition the retail business to a full-fledged strategic partner for both customers and partners.”
Poehler joins Toshiba with extensive retail commerce solutions experience and insight. During his tenure as President of Panasonic Systems Communications Company of North America he led a $1.1 billion division morphing it from a product-centric organization to an end-to-end provider of innovative retail solutions in the areas of mobility, point-of-sale, digital signage, computer vision, and analytics that helped Fortune 1000 companies understand shopper demographics and behavior, improve associate engagement and create better customer experiences. While at Dell Technologies he served as vice president of worldwide sales for its cloud client computing team that represents a full suite of cloud and desktop virtualization solutions for retail that enabled scalable thin client solutions. Poehler’s experience also includes Pivot3 where he served as Chief Revenue Officer responsible for leading the global sales organization and executing on the company’s growth strategy and talent acquisition as they developed and went to market with a hyper-converged software platform that manages mixed workloads including IOT-surveillance, analytics, and hybrid cloud solutions.
“The retail industry is looking for new and innovative ways to adapt more quickly to customer needs while they optimize store operations and reduce the cost of delivering and managing their business. Toshiba has a strong worldwide retail position and is on the verge of disrupting the industry with their intelligent end-to-end solutions,” said Poehler. “I’m honored and excited about the opportunity to help this world-class retail commerce solutions business grow in ways that support our partner community, and helps our clients delight their customers while becoming even greater merchants.”
About Toshiba Global Commerce Solutions
Toshiba Global Commerce Solutions is a global market share leader in retail store technology and retail’s first choice for integrated in-store solutions. Together with a global team of dedicated business partners, we achieve brilliant commerce by advancing the future of retail with innovative commerce solutions that enhance customer engagement, transform the in-store experience, and accelerate digital transformation. To learn more, visit commerce.toshiba.com and engage with us on Twitter, LinkedIn, Facebook and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005083/en/
Contact information
Fredrik Carlegren
Vice President of Marketing
(984) 444-2769
fcarlegren@toshibagcs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom